Systemic anti-PD-L1 therapy at 5 days post-radiation offered enhanced delivery of the therapeutic antibody to the tumor through damaged, leaky blood vessels and upregulated PD-L1 expression on cancer cells, resulting in the induction of strong anti-cancer immune response. The gene discussed is CD274; the disease is neoplasm.